---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023210"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:27:18.071150+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023

## Summary
- Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.
- Revenue $16.9M for Q3 2022 vs $17.6M for Q3 2021, down ~4%.
- R&D expense $30.4M, G&A $10.5M; restructuring charges $7.1M in Q3.
- IND for CX-2051 and CX-801 expected H2 2023; CX-2029 sqNSCLC data update Q4 2022.
- Company restructuring announced July 2022 to be completed by end of 2022; total ~$7.9M.

## SEC filing metadata
- accession: 0000950170-22-023210
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/0000950170-22-023210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/ctmx-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023210
- JSON: https://secwatch.observer/filing/0000950170-22-023210.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023210.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for for the three months and nine months ended September 30, 2022.
  - Period: for the three months and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017022023210/0000950170-22-023210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.